ARMS Technology License Extended

Under an extension to a license agreement with AstraZeneca, BTG (London, UK) and DxS Genotyping (Manchester, UK) are now able to grant licenses to the amplification refractory mutation system (ARMS).

ARMS is a simple but reliable and widely used method for the detection of genetic mutations and single nucleotide polymorphisms (SNPs). The ability to grant licenses to this method now places the major rights with one licensor. The initial agreement with AstraZenca was signed in March 2004. The new extension will allow BTG and DxS to maximize the commercial value of the ARMS technology by granting licenses to companies that offer products and services related to the detection of genetic variation and thereby encourage new and novel applications.

Although more than 99% of human DNA sequences are the same, variations in DNA sequence can have a major impact on how humans respond to disease, environmental challenges, and drugs and other therapies. Scientists believe SNP maps will help them identify the multiple genes associated with such complex diseases as cancer, diabetes, and vascular disease. In addition, SNPs can be useful in predetermining an individual's response to drugs and can be used as markers to differentiate individuals with varying responses to treatment.

The nucleic acid diagnostic market, estimated at U.S.$1.9 billion, includes testing for infectious and genetic diseases as well as cell and tissue typing, cancer genetics, and personalized medicine. ARMS technology, noted BTG and DxS, has applications throughout this market.






Related Links:
BTG
DxS